TABLE 1.
Basic characteristics of the included studies
Study | I | Case no. I/C (patient no.) | Treatment interval/sessions for PRP | Treatment interval/sessions for “A” | Follow‐up duration | Adverse events (cases no. of I/C) |
---|---|---|---|---|---|---|
Deng et al 18 | EL + PRP | 20/20 (40) | 1 month/3 | Twice a week/24 | 3 months | None |
Khattab et al 19 | EL + PRP | 26/26 (52) | 3 weeks/6 | Twice a week/32 | 3 months | Pain (6/0), erythema (0/4) |
Le 20 | EL + PRP | 24/60 (84) | 1 week/NR | Once or twice a week/15 | 12 months | Pain (NR), recurrence (1/13) |
Li et al 21 | EL + PRP | 40/40 (40) | 3 weeks/3 | Twice a week/18 | 3 months | Pain (40/0), erythema (1/1) |
Abdelghani et al 12 | FCL + PRP | 20/20 (40) | 3 weeks/4 | Biweekly/4 | 3 months | Erythema (NR) |
Kadry et al 22 | FCL + PRP | 30/30 (30) | 2 weeks/6 | biweekly/6 | 3 months | Pain (7/10), hyperpigmentation (2/8), erythema (NR) |
Mrigpuri et al 23 | NCES + PRP | 25/25 (20) | NA | NA | 16 weeks | None |
Parambath et al 24 | NCES + PRP | 20/20 (20) | NA | NA | 3, 6 months | None |
Ibrahim et al 13 | NB‐UVB + PRP | 60/60 (60) | 2 weeks/8 | Twice a week/16 | 3 months | Pain: 30, ecchymosis: 9 |
Kale et al 25 | NB‐UVB + PRP | 32/32 (64) | 2 weeks/8 | Biweekly/8 | 2, 4 months | Pain: 15/17, ecchymosis: 3/2 |
El‐Raheem et al 26 | Vitamin D + PRP | 20/20 (40) | 1 month/3 | 1 month/3 | 3 months | None |
Abbreviations: “A”, EL, FCL, NCES, NB‐UVB, or vitamin D; C, control; EL, excimer laser; FCL, fractional carbon dioxide laser; I, intervention; PRP, platelet‐rich plasma; NA, not applicable; NB‐UVB, narrowband‐ultraviolet B; NCES, non‐cultured epidermal cell suspension; NR, not reported.